Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia

• Status: Not yet recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

An unpublished study by the investigators on healthy participants has shown that the supplementation of oil palm phenolics (OPP) at 250 mg is the optimum dose to demonstrate the ability to lower total and LDL cholesterol. There is no clinical evidence as yet on that optimum dosage of OPP supplementation in improving fasting lipid profile in minor hyperlipidemia subjects. The investigators hypothesize that in a clinical study, OPP supplemented to the minor hyperlipidemic participants will elicit a reduction in total and LDL cholesterol while maintaining safety and tolerability. OPP may have the potential to be positioned as natural health supplement in improving lipid profile.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Isa Naina Mohamed
• Collaborator: Malaysia Palm Oil Board

Criteria

Inclusion Criteria:

• Elevated Fasting Total cholesterol level of more than 5.2 mmol/L

• Elevated Fasting LDL cholesterol of more than 3.36 mmol/L*

• Elevated Fasting Triglycerides of more than 1.69 mmol/L*

• Willing to remain staying in Klang Valley area in the case of Movement Control Order implementation.

Exclusion Criteria:

• Elevated Total cholesterol level of more than 6.2 mmol/L

• Elevated LDL cholesterol of more than 4.9 mmol/L

• Elevated Triglycerides of more than 5.6 mmol/L

• Smoking

• Habitual alcohol consumption

• Consuming antioxidant supplement

• Pregnant/ breastfeeding

• Medical history of cardiovascular disease, diabetes, dyslipidemia, familial hyperlipidemia, hypothyroidism, kidney disease and endocrine disease.

• Current use of lipid-lowering medication